TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant schwannomas

Tumor Biology

Volumn 39, Issue 5, 2017, Pages

  Li, Zhao ^a   Liu, Xiaobing ^a   Guo, Rongbin ^a   Wang, Pengfei ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxic T cell; PD 1; Schwannoma; TIM 3

Indexed keywords

ECALECTIN; GAMMA INTERFERON; GRANZYME B; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERLEUKIN 2; PROGRAMMED DEATH 1 RECEPTOR; HAVCR2 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; LYMPHOCYTE PROLIFERATION; MALIGNANT NEURILEMOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; MALE; NEURILEMMOMA; PATHOLOGY; REGULATORY T LYMPHOCYTE;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOTHERAPY; MALE; NEURILEMMOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 85020045109     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317698352     Document Type: Article

References (44)

1. White HR. Survival in malignant schwannoma. An 18-year study. Cancer 1971; 27: 720-729.
2. Propp JM, McCarthy BJ, Davis FG, et al. Descriptive epidemiology of vestibular schwannomas. Neuro Oncol 2006; 8: 1-11.
3. Wilkinson JS, Reid H and Armstrong GR. Malignant transformation of a recurrent vestibular schwannoma. J Clin Pathol 2004; 57: 109-110.
4. Porter DE, Prasad V, Foster L, et al. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma 2009; 2009: 756395.
5. Shin M, Ueki K, Kurita H, et al. Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. Lancet 2002; 360: 309-310.
6. Ahmad RA, Sivalingam S, Topsakal V, et al. Rate of recurrent vestibular schwannoma after total removal via different surgical approaches. Ann Otol Rhinol Laryngol 2012; 121: 156-161.
7. Cashen DV, Parisien RC, Raskin K, et al. Survival data for patients with malignant schwannoma. Clin Orthop Relat Res 2004; 69-73.
8. Gajewski TF, Schreiber H and Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14: 1014-1022.
9. Friedman K, Prieto P, Devillier L, et al. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother 2012; 35: 400-408.
10. Gu-Trantien C, Loi S, Garaud S, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123: 1-20.
11. Mahmoud SMA, Paish EC, Powe DG, et al. Tumorinfiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-1955.
12. Kmiecik J, Poli A, Brons NHC, et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol 2013; 264: 71-83.
13. Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207: 637-650.
14. Fu J, Zhang Z, Zhou L, et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 2013; 58: 139-149.
15. Klebanoff CA, Gattinoni L and Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211: 214-224.
16. Kochenderfer JN and Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10: 267-276.
17. Balkwill F, Montfort A and Capasso M. B regulatory cells in cancer. Trends Immunol 2013; 34: 169-173.
18. Rahir G and Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother 2012; p. 751-759.
19. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
20. Gabrilovich DI, Ostrand-Rosenberg S and Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268.
21. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-1174.
22. Jarnicki AG, Lysaght J, Todryk S, et al. Suppression of antitumor immunity by IL-10 and TGF-β-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006; 177: 896-904.
23. Massagué J. TGFbeta in cancer. Cell 2008; 134: 215-230.
24. Pellerin L, Jenks JA, Bégin P, et al. Regulatory T cells and their roles in immune dysregulation and allergy. Immunol Res 2014; 358-368.
25. Taube JM, Klein AP, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 1: 5064-5075.
26. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
27. Rabinovich GA, Gabrilovich D and Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296.
28. Yousem SA, Colby TV and Urich H. Malignant epithelioid schwannoma arising in a benign schwannoma. A case report. Cancer 1985; 55: 2799-2803.
29. Tosato G and Cohen JI. Generation of Epstein-Barr Virus (EBV)-immortalized B cell lines. Curr Protoc Immunol 2007; Chapter 7: Unit 7.22.
30. Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-2194.
31. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008; 205: 2763-2779.
32. McMahan RH, Golden-Mason L, Nishimura MI, et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010; 120: 4546-4557.
33. Punt S, Thijssen VL, Vrolijk J, et al. Galectin-1,-3 and-9 expression and clinical significance in squamous cervical cancer. PLoS One 2015; 10: e0129119.
34. Oomizu S, Arikawa T, Niki T, et al. Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion. PLoS One 2012; 7: e48574.
35. Stromnes IM, Schmitt TM, Chapuis AG, et al. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev 2014; 257: 145-164.
36. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
37. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709-2720.
38. Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-2186.
39. Yang Z-Z, Grote DM, Ziesmer SC, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012; 122: 1271-1282.
40. Mujib S, Jones RB, Lo C, et al. Antigen-independent induction of Tim-3 expression on human T cells by the common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J Immunol 2012; 188: 3745-3756.
41. Shayan G and Ferris RL. PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL. J Immunother Cancer 2015; 3: P196.
42. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
43. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
44. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.